Format

Send to

Choose Destination
Eur Neurol. 2000;44(4):236-41.

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

Author information

1
Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202-5111, USA. mfarlow@iupui.edu

Abstract

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.

PMID:
11096224
DOI:
10.1159/000008243
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center